

Long-Acting G-CSF: Part B Coverage

Effective: July 1, 2020

Covered Products

- Neulasta and Neulasta OnPro
- Udenyca
- Fulphila
- Nyvepria
- Ziextenzo

Coverage Details	
Covered Uses	All FDA-approved indications and indications per the Local Coverage Determinations (LCDs) and National Coverage Determinations (NCDs)
Exclusion Criteria	None
Additional Coverage Information	Tufts Health Plan recommends the use of Neulasta/Neulasta OnPro or Udenyca as the most cost effective long-acting G-CSF products.